Page 2 - Henner Kollenberg News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Glycotope Announces New Strategy to Maximize Potential of Uniquely-Tumor Specific Antibody Platform

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Chris welshGlycotope gmbChris gardnerPatrik kehlerAntje danielczykHenner kollenbergResearch developmentConsilium strategic communicationsGlycotope announces new strategyMaximize potentialUniquely tumor specific antibodyChief executive officerChief operating officerChief scientific officerGlobe newswire

Glycotope to spin-out its Service Business to the newly formed FyoniBio GmbH

Glycotope to spin-out its Service Business to the newly formed FyoniBio GmbH Berlin, Germany, February 1, 2022 - Glycotope GmbH, a biotechnology company developing antibodies against proteins carrying

Berlin buchXiao shenChris gardnerFyonibio gmbCanton biologicsCantonbio deutschland gmbChris welshGlycotope gmbKostenloser wertpapierhandelHans baumeisterHenner kollenbergCanton biologics coCanton biologics co ltdCanton biologics groupService businessConsilium strategic communications

Byondis and Glycotope Enter Platform Access Agreement for Discovery and Development of Antibodies Against Novel GlycoTargets

Byondis and Glycotope Enter Platform Access Agreement for Discovery and Development of Antibodies Against Novel GlycoTargets
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.

Wim dokterHenner kollenbergDevelopment of antibodiesGlycotope enter platform access agreementAntibodies againstByondis chief scientific officer wim dokterManaging directorGood manufacturing practiceவளர்ச்சி ஆஃப் ஆன்டிபாடிகள்ஆன்டிபாடிகள் எதிராகநிர்வகித்தல் இயக்குனர்நல்ல உற்பத்தி ப்ர்யாக்டீஸ்

Investegate |Glycotope Announcements | Glycotope: Byondis and Glycotope Enter Platform Access Agreement for Discovery and Development of Antibodies Against Novel GlycoTargets

Investegate |Glycotope Announcements | Glycotope: Byondis and Glycotope Enter Platform Access Agreement for Discovery and Development of Antibodies Against Novel GlycoTargets
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

Chris welshGlycotope gmbChris gardnerWim dokterVerhoeven yvonne massarHenner kollenbergCorporate communications public eyes healthcareDevelopment of antibodies against novel glycotargetsConsilium strategic communicationsGlycotope enter platform access agreementAntibodies against novelByondis chief scientific officer wim dokterManaging directorGood manufacturing practiceGlycotope gmbhConsilium strategic

Byondis and Glycotope Enter Platform Access Agreement for Discovery and Development of Antibodies Against Novel GlycoTargets

Byondis and Glycotope Enter Platform Access Agreement for Discovery and Development of Antibodies Against Novel GlycoTargets
prnewswire.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.co.uk Daily Mail and Mail on Sunday newspapers.

Prnewswire byondisWim dokterHenner kollenbergByondis chief scientific officer wim dokterManaging directorGood manufacturing practiceநிர்வகித்தல் இயக்குனர்நல்ல உற்பத்தி ப்ர்யாக்டீஸ்